Also known as Xifaxan
Rifaximin is a semisynthetic antibiotic based on rifamycin. It has poor oral bioavailability, meaning that very little of the drug will be absorbed into the blood stream when it is taken orally. Rifaximin is used in the treatment of traveler's diarrhea and hepatic encephalopathy, for which it received orphan drug status from the U.S. Food and Drug Administration in 1998.Source: Wikipedia
Estimated Total Cost: $680.24 for an average of 21 days supply
Patients are most commonly prescribed rifaximin to treat viral hepatitis, cirrhosis, rabies, and pick disease.